## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.6% below STRENGTH zone (4.0-10.0%); PEG 4.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($646.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Investors in IDEXX Laboratories (NASDAQ:IDXX) have seen respectable returns of 65% over the past year**
- Source: Simply Wall Street | 20251231T100817 | Bullish | Relevance: 100%
- IDEXX Laboratories (NASDAQ:IDXX) shareholders have experienced a 65% return over the past year, significantly outperforming the broader market. This strong stock performance is attributed to the company's 21% EPS growth, which has led to a favorable market sentiment reflected in a high P/E ratio. The article suggests that this positive momentum might indicate a good time for investors to further examine the company.

**2. Investors in IDEXX Laboratories (NASDAQ:IDXX) have seen respectable returns of 65% over the past year**
- Source: Simply Wall Street | 20251231T100803 | Bullish | Relevance: 100%
- IDEXX Laboratories Inc. (NASDAQ:IDXX) has delivered a 65% return to investors over the past year, significantly outperforming the broader market. This strong performance is supported by a 21% growth in EPS and a favorable market sentiment reflected in its P/E ratio. The company also boasts a 62% gain over three years, delighting long-term shareholders.

**3. Precision Trading with Idexx Laboratories Inc. (IDXX) Risk Zones**
- Source: Stock Traders Daily | 20251229T061600 | Somewhat-Bearish | Relevance: 100%
- This article discusses precision trading strategies for Idexx Laboratories Inc. (IDXX) based on AI-generated risk zones. It highlights a weak near and mid-term sentiment but a strong long-term outlook, presenting specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis emphasizes an exceptional risk-reward short setup with a 25.9:1 ratio.

**4. VIRGINIA RETIREMENT SYSTEMS ET Al Has $49.07 Million Stake in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251231T115750 | Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 29.5% in the third quarter, now holding 76,808 shares valued at $49.07 million. Analyst sentiment is generally positive, with a "Moderate Buy" rating and an average price target of $763.50. IDEXX Laboratories recently surpassed quarterly earnings estimates and provided optimistic FY2025 guidance.

**5. Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?**
- Source: Yahoo Finance Singapore | 20251229T150825 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) stock has outperformed its Medical sector peers this year, gaining 66.5% compared to the sector's average of 8.2%. The company, holding a Zacks Rank #2 (Buy), also shows strong analyst sentiment with a 2.5% increase in its full-year earnings estimate over the past 90 days. Artivion (AORT) is another medical stock demonstrating strong performance within the same industry group as IDEXX.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.06 signals overvaluation risk, limited margin of safety. Forward P/E 46.9x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.1B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.06 |
| Forward P/E | 46.9 |
| Current P/E | 52.4 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.2% to -2.6% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). AM_20 at -3.1% indicates price below own 20MA trend. Underperforming sector by 3.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-3.56), momentum weakening. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.59% (CS: 16) | Weak |
| RSI_14 | 38.7 | Neutral |
| MACD Histogram | -3.56 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 1.164x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $676.53
- **Stop Loss:** $646.15 (4.5% risk)
- **Target:** $706.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $31,796.91
- **Portfolio %:** 31.80%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*